Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

Patent metadata

Field	Value
Publication number	US-11241460-B2
Application number	US-201816025788-A
Country	US
Kind code	B2
Filing date	Jul 2, 2018
Priority date	Mar 15, 2013
Publication date	Feb 8, 2022
Grant date	Feb 8, 2022

Abstract

Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.

First claim

The invention claimed is:

1. A method of improving visual acuity in a subject having end stage retinal degeneration caused by loss of photoreceptors, comprising
administering to the sub-retinal space of the subject a preparation of photoreceptor progenitor cells, wherein at least 70% of the cells in the preparation are immunocytochemically PAX6(+) and CHX10(−), wherein the subject is characterized as having eyesight of 20/200 or worse prior to administration, and wherein administration of the preparation results in improved visual acuity.

2. The method of claim 1 , wherein the subject is human and the photoreceptor progenitor cells are human.

3. The method of claim 1 , wherein the photoreceptor progenitor cells are derived in vitro from pluripotent stem cells.

4. The method of claim 3 , wherein the pluripotent stem cells are selected from the group consisting of embryonic stem cells and induced pluripotent stem cells.

5. The method of claim 1 , wherein the photoreceptor progenitor cells are HLA-genotypically identical to each other.

6. The method of claim 1 , wherein the photoreceptor progenitor cells are genomically identical to each other.

7. The method of claim 1 , wherein a majority of the photoreceptor progenitor cells in the preparation is mRNA transcript positive for Nr2e3, Tr2, ROR and NRL as detected by qPCR.

8. The method of claim 1 , wherein the photoreceptor progenitor cells express at least 2-fold more, relative to retinal neural progenitor cells, of one or more markers selected from uPA, Tenascin-C, CXCL16, CX3CL1 and Chitinase 3 like-1, as detected by immunoassay of secreted proteins or mRNA transcript levels by qPCR.

9. The method of claim 1 , wherein the photoreceptor progenitor cells have replicative capacity to undergo at least 20 population doublings in cell culture with less than 25 percent of the cells undergoing cell death, senescing or differentiating into phenotypically nonphotoreceptor cells by the 20th doubling.

10. The method of claim 1 , wherein the photoreceptor progenitor cells have transferrin protein and or transferrin mRNA levels that are at least 25 percent less than glyceraldehyde 3-phosphate dehydrogenase protein or mRNA levels respectively.

11. The method of claim 1 , wherein the photoreceptor progenitor cells maintain plasticity to differentiate into both rods and cones.

12. The method of claim 1 , wherein the preparation includes less than 1% pluripotent stem cells.

13. The method of claim 1 , wherein the photoreceptor progenitor cells are at least 75%, at least 85%, at least 95%, at least 99% or about 100% pure with respect to other cell types.

14. The method of claim 1 , wherein the photoreceptor progenitor cells are administered in suspension.

15. The method of claim 1 , wherein the photoreceptor progenitor cells are administered on a matrix or a support.

16. The method of claim 1 , wherein the photoreceptor progenitor cells are administered at a dose of about 10 3 -10 4 cells.

17. The method of claim 1 , wherein the subject is characterized as having eyesight worse than 20/200.

18. The method of claim 1 , wherein the preparation of photoreceptor progenitor cells is pyrogen-free and mycogen-free.

19. The method of claim 1 , wherein the photoreceptor progenitor cells are mRNA transcript positive for recoverin, opsin and rhodopsin.

20. The method of claim 3 , wherein the in vitro differentiation of pluripotent stem cells comprises differentiating the pluripotent stem cells into eye field progenitor cells under adherent conditions, and differentiating the eye field progenitor cells into the photoreceptor progenitor cells.

21. The method of claim 1 , wherein the photoreceptor progenitor cells are capable of differentiating into photoreceptor cells in vitro.

22. The method of claim 21 , wherein the photoreceptor progenitor cells are capable of differentiating differentiate into photoreceptor cells in vitro in the presence of retinoic acid and taurine.

23. The method of claim 21 , wherein the photoreceptor cells express rhodopsin, opsin, recoverin, and PDE6a.

Assignees

• Astellas Inst For Regenerative Medicine

Inventors

• Lanza Robert P
• Lu Shi-Jiang
• Wang Wei

Classifications

• A61K35/545

  Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title

• C12N2506/02

  from embryonic cells · CPC title

• C12N5/062

  Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain · CPC title

• C12N5/0623

  Stem cells · CPC title

• C12N2501/105

  Insulin-like growth factors [IGF] · CPC title